Alkem Laboratories Ltd

Alkem Laboratories Management Change

Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.

Alkem Laboratories Debt & Borrowing: ₹593.5 Cr

Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.

Value

₹593.5 Cr

Alkem Laboratories Product Launch

Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.

Alkem Laboratories Management Change

Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.

Alkem Laboratories Product Launch

Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.

Alkem Laboratories Investor Presentation: Key Takeaways

Alkem reported Q1FY27 revenue of INR 3,740cr, up 11% YoY. India sales grew 10.3%, while International jumped 16%. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation.

Call

Guides 12% growth

Alkem Laboratories Q1 FY27 Results: Net Profit ₹521 Cr, Down 22.0% YoY

Alkem Laboratories Ltd reported revenue from operations of ₹3,740 Cr (+10.9% YoY) and net profit of ₹521 Cr (-22.0% YoY) for Q1 FY27.

Key figure

Net profit ₹521 Cr · -22.0% YoY

Alkem Laboratories Earnings Call: Key Takeaways

Alkem reported strong FY26 results with landmark INR 3,000cr+ EBITDA. Strategy focuses on chronic therapy growth in India and international expansion, particularly with the semaglutide launch.

Alkem Laboratories Q4 FY26 Results: Net Profit ₹236.5 Cr, Down 22.7% YoY

Alkem Laboratories Ltd reported revenue from operations of ₹3,603 Cr (+14.6% YoY) and net profit of ₹236.5 Cr (-22.7% YoY) for Q4 FY26.

Key figure

Net profit ₹236.5 Cr · -22.7% YoY

Alkem Laboratories Q4 FY26 Results: Net Profit ₹251.1 Cr, Down 22.1% YoY

Alkem Laboratories Ltd reported revenue from operations of ₹3,603 Cr (+14.6% YoY) and net profit of ₹251.1 Cr (-22.1% YoY) for Q4 FY26.

Key figure

Net profit ₹251.1 Cr · -22.1% YoY